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AbsTrACT
Objective To report outcomes at 2 years corrected 
age for children of women recruited to a trial comparing 
alternative policies for timing of cord clamping and 
immediate neonatal care at very preterm birth.
Design Parallel group randomised (1:1) trial.
setting Eight UK tertiary maternity units.
Participants Two hundred and seventy-six babies born 
to 261 women expected to have a live birth before 32+0 
weeks’ gestation.
Interventions Deferred cord clamping (≥2 min) and 
immediate neonatal care with cord intact or immediate 
(≤20 s) clamping and immediate neonatal care after 
clamping.
Main outcome measure Composite of death or 
adverse neurodevelopmental outcome at 2 years 
corrected age.
results Six babies born after 35+6 weeks were 
excluded. At 2 years corrected age, outcome data 
were not available for a further 52 children, leaving 
218 for analysis (115 deferred clamping, 103 
immediate clamping). Overall, 24/115 (21%) children 
allocated deferred clamping died or had an adverse 
neurodevelopmental outcome compared with 35/103 
(34%) allocated immediate clamping; risk ratio (RR) 
0.61 (95% CI 0.39 to 0.96); risk difference (RD) −13% 
(95% CI −25% to −1%). Multiple imputation for missing 
data gave an RR 0.69 (95% CI 0.44 to 1.09) and RD 
−9% (95% CI −21% to 2%).
Conclusions Deferred clamping and immediate 
neonatal care with cord intact may reduce the risk 
of death or adverse neurodevelopmental outcome 
at 2 years of age for children born very premature. 
Confirmation in larger studies is needed to determine the 
real benefits and harms.
Trial registration number ISRCTN21456601.
InTrODuCTIOn
Although just 1.1% of live births in the UK are very 
preterm (before 32 weeks’ gestation), these infants 
account for 43% of neonatal deaths.1 Those who 
survive are at increased risk for a range of neuro-
developmental sequelae including cerebral palsy, 
neurosensory and cognitive impairment, and atten-
tion, social and emotional problems.2 3 Such diffi-
culties can have a major impact on a child’s health, 
well-being and academic attainment and may 
persist into adulthood.4 5 Interventions that could 
provide even a modest improvement in long-term 
outcomes would be of substantial benefit to these 
children and their families.
Systematic reviews have suggested that defer-
ring clamping of the umbilical cord at preterm 
birth may reduce the risk of intraventricular 
haemorrhage (IVH)6 and death before hospital 
discharge.6 7 However, the trials largely excluded 
infants requiring immediate resuscitation at birth, 
and for very preterm births, most trials deferred 
clamping for 60 s or less. Also, data on long-term 
safety are sparse. The Cord Pilot Trial compared 
alternative policies for cord clamping and imme-
diate neonatal care for very preterm births and 
results to discharge have been reported.8 This paper 
presents follow-up of the children after discharge 
and the results of neurodevelopmental assessments 
at 2 years corrected age.
MeThODs
The Cord Pilot Trial was conducted at eight UK 
hospitals, and the protocol is published.9 10 Women 
expected to have a live birth before 32+0 weeks’ 
gestation (very preterm) were randomised 1:1 either 
to deferred cord clamping after at least 2 min and, 
if needed, immediate neonatal care with cord intact 
or to immediate clamping within 20 s and neonatal 
What is already known on this topic?
 ► A short delay in umbilical code clamping 
may reduce the risk of death before hospital 
discharge at very preterm birth.
 ► Immediate neonatal care can be provided 
with the cord intact, allowing cord clamping 
to be deferred for longer in babies requiring 
resuscitation at birth.
 ► Previous trials have been small, and few have 
reported outcomes beyond discharge from 
hospital.
What this study adds?
 ► Neurodevelopmental assessment at 2 years 
corrected age is feasible using a range of 
strategies, including routine clinical data.
 ► Deferred clamping with immediate neonatal 
care, if needed, may reduce the risk of death 
or adverse neurodevelopmental outcome at 2 
years of age.
 ► Large high-quality trials and meta-analysis of 
individual participant data from these trials are 
needed to confirm the true benefits and harms.
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care after clamping. To ensure women could be recruited when 
birth was imminent, we included a two-stage consent pathway, 
with oral assent for recruitment followed by written consent after 
the birth, alongside the usual one stage pathway (described in 
detail elsewhere8 9). Between March 2013 and February 2015, 
261 women were randomised with six excluded as birth was after 
35+6 weeks.8 Of the remaining 255 women, 17 had a twin preg-
nancy, for two of which one fetus died in utero before randomisa-
tion, leaving 270 children for the analysis of outcomes at hospital 
discharge.8 Of these, 22 babies died before discharge (including 
three stillbirths), and a further two died after discharge, giving a 
total of 24 deaths. Eight children were excluded from follow-up 
either because the mother had already withdrawn consent (n=6) 
or she gave oral assent for recruitment,8 and subsequent consent 
for follow-up was not available (n=2). Therefore, 238 children 
were eligible for assessment (figure 1).
Parent and parent representative involvement
Parent and parent representative involvement has been 
reported.8 For the follow-up, parent representatives contrib-
uted to study design and materials, including the process for 
contacting families.
neurodevelopmental assessment of children
Children were assessed using the parent-completed Ages and 
Stages Questionnaire-3 (ASQ-3)11 and the Bayley Scales of 
Figure 1 Flow for follow-up of children at 2 years (corrected age). ASQ-3, Ages and Stages Questionnaire-3.
copyright.
 o
n
 2 August 2019 by guest. Protected by
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2019-316912 on 1 August 2019. Downloaded from
 
F3Armstrong-Buisseret L, et al. Arch Dis Child Fetal Neonatal Ed 2019;0:F1–F7. doi:10.1136/archdischild-2019-316912
Original article
Infant and Toddler Development, Third Edition (Bayley-III).12 
If neither assessment was conducted, routine clinical data for 
2-year outcomes were obtained if available.
Shortly before children reached 2 years corrected age, the 
ASQ-3 was posted to the mother along with an invitation for a 
Bayley-III assessment. If a completed ASQ-3 was not returned, 
the family was contacted with up to two reminder letters and 
a phone call. If no ASQ-3 was returned, parents were asked to 
complete the appropriate version (24, 27 or 30 months) during 
the home visit prior to the Bayley-III assessment or during a 
hospital visit. If >1 ASQ-3 was returned, the one completed 
closest to the date the child was 2 years corrected age was used 
for analysis.
The ASQ-3 includes 30 questions covering five domains: 
communication, fine motor skills, gross motor skills, problem 
solving and personal-social skills. The response to each question 
is ‘not yet’, ‘sometimes’ or ‘yes’ (scored 0, 5 and 10, respec-
tively). For each domain, scores are summed to produce a total. 
The domain score is not calculated if ≥3 responses are missing. If 
one or two responses are missing, the domain score is calculated 
using the mean of the completed items to impute the missing 
items. Four further questions to assess hearing, vision and gross 
motor function were added to the ASQ-3 questions.13
The Bayley-III comprises three scales to assess cognitive, 
language and motor development.12 Children were assessed 
during a home visit by a trained researcher (KP) blind to 
intervention allocation. Three assessments were video recorded 
and scored by an independent observer (SJ) to assess inter-rater 
reliability.
Outcome measures
The main outcome was a composite of death or adverse neuro-
developmental outcome at 2 years corrected age. Secondary 
outcomes included the individual components of the composite.
Classification of adverse neurodevelopmental outcome
Neurodevelopmental outcomes were classified using the 
Bayley-III scores if available.14 15 If the child did not have a 
Bayley-III assessment, or individual scales could not be completed, 
ASQ-3 data plus our additional questions on hearing, vision and 
gross motor function were used. To account for underestimation 
of developmental delay using the Bayley-III, moderate or severe 
impairment was based on scores >1 SD below the normative 
mean (scores <85).14 15 For each ASQ-3 domain, developmental 
delay was based on a total score >2 SDs below the mean using 
published norms.11
Children were classified as having an adverse neurodevelop-
mental outcome if they met the criteria for a moderate/severe 
impairment in any one of five functions: motor, cognitive, speech/
language, hearing or vision (see online supplementary appendix 
1).16 For motor, this was defined as a Bayley-III gross motor scale 
Table 1 For children included in analysis of outcomes to discharge and outcome at 2 years, characteristics at entry and outcomes to discharge
Included in analysis of outcomes to discharge Included in analysis of outcomes at 2 years
Clamp ≥2 min Clamp ≤20 s Clamp ≥2 min Clamp ≤20 s
n=135 (%) n=134 (%)* n=115 (%) n=102 (%)*
Women’s age (years) mean (SD) 30.5 (6.3) 29.4 (6.7) 30.1 (5.8) 29.8 (6.6)
Gestation at birth (weeks)
  Median (25th, 75th centile) 29 (27.1, 30.7) 29.1 (27.6, 30.4) 29 (27.1, 30.7) 29 (27.0, 30.3)
Two-stage consent pathway 36 (27) 37 (28) 30 (26) 31 (30)
Twin pregnancy 12 (9) 20 (15) 10 (9) 14 (14)
Caesarean delivery 86 (64) 73 (54) 74 (64) 56 (55)
Baby sex
  Male 71 (53) 72 (54) 58 (50) 60 (59)
For live births n=134 n=132 n=114 n=100
Any IVH (grade 1–4) 43 (32) 47 (36) 36 (32) 35 (35)
Severe IVH (grade 3 or 4) 6 (4) 7 (5) 4 (4) 5 (5)
Periventricular leucomalacia 7 (5) 8 (6) 6 (5) 5 (5)
Blood transfusion 63 (47) 68 (52) 53 (46) 58 (58)
Jaundice requiring treatment 123 (92) 120 (91) 105 (92) 89 (89)
Chronic lung disease† 40 (31) 39 (33) 31 (28) 31 (35)
Ventilation 100 (75) 103 (78) 84 (74) 80 (80)
Necrotising enterocolitis 8 (6) 5 (4) 7 (6) 4 (4)
Sepsis‡ 72 (54) 80 (61) 59 (52) 63 (63)
Treatment for patent ductus arteriosis 20 (15) 20 (15) 15 (13) 19 (19)
Duration of hospital stay (nights)§
  Median (25th, 75th centile) 57 (39, 85) 57 (37, 75) 57 (38, 80) 60 (40, 83)
Receiving mother’s breast milk at discharge§¶ 71 (55) 68 (57) 61 (56) 55 (63)
*One woman withdrew (outcome data reported only for death before discharge).
†For babies surviving to 36 weeks postmenstrual age. n=129 clamping ≥2 min, n=120 clamping ≤20 s for all children and n=109, n=88 respectively for children included in 
analysis at 2 years.
‡Clinical sepsis defined as positive culture and ≥5 days antibiotics or negative culture and ≥5 days antibiotics.
§For babies alive at discharge n=128 clamping ≥2 min, n=120 clamping ≤20 s for all children and n=108, n=88 respectively for children included in analysis at 2 years.
¶Receiving breast milk at discharge not known for three babies in the clamp cord ≥2 min group (two included in analysis at 2 years) and one baby in clamp cord ≤20 s group 
(not included in analysis at 2 years).
IVH, intraventricular haemorrhage.
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score <7. If this scale had not been completed, assessment was 
based on our additional gross motor function questions from 
the ASQ-3, that is, if the child was unable to walk without assis-
tance or sit without support. For cognitive and speech/language 
functions, this was defined as having a composite score <85 
on the relevant Bayley-III scale. If these scales had not been 
completed, assessment was based on a score below the relevant 
domain cut-off on the ASQ-3 (problem solving for cognition and 
communication for language). Hearing and vision were assessed, 
respectively, as moderate/severely impaired if the child required 
hearing aids or was deaf, or had difficulty seeing with glasses, 
could only see light or was blind.
blinded review of neurodevelopmental outcome
A blinded review of outcome data was undertaken if: clinical 
follow-up data only were available, the Bayley-III was not fully 
completed, the ASQ-3 was not completed within the correct 
timeframe or the additional questions included on the ASQ-3 
about hearing and vision were not completed. For each child, 
data were assessed independently by two reviewers blind to the 
allocated group. Discrepancies were resolved by discussion or if 
needed by a third independent reviewer.
statistical analyses
As this was planned as a pilot trial, there was no formal power 
calculation.9 10 All analyses are based on the groups as randomly 
allocated (intention to treat) and were carried out using Stata SE 
15.1. The main outcome (death or adverse neurodevelopmental 
outcome) is summarised by allocated group and presented with a 
risk ratio (RR), risk difference (RD) and 95% CIs. Each compo-
nent of the main outcome is also summarised by group.
Multiple imputation using chained equations17 was used as 
a sensitivity analysis to include children with missing outcome 
data in order to explore their potential impact on the estimate 
of RR and RD. Variables included in the imputation model were 
maternal age, gestation at birth, mode of delivery, sex, receiving 
breast milk at discharge, necrotising enterocolitis, grade of 
IVH, bronchopulmonary dysplasia, treatment for retinopathy 
of prematurity and country specific decile of Index Multiple 
Deprivation.18 Thirty datasets were imputed, and estimates were 
combined using Rubin’s rules.17 This sensitivity analysis assumed 
that missing outcomes were missing at random,19 that is, condi-
tional on the observed variables the distribution of the observed 
and missing outcomes are assumed to be the same.
Table 3 For children alive at 2 years (corrected age) outcomes at discharge according to availability of developmental outcome data and 
allocated group
Clamp ≥2 min+neonatal care with cord intact
Clamp ≤20 s
+neonatal care after clamping
neurodevelopmental 
data not available
n=20 (%)
neurodevelopmental 
data available
n=107 (%)
neurodevelopmental 
data not available
n=32 (%)
neurodevelopmental 
data available
n=87 (%)
Any IVH (grade 1–4) 7 (35) 30 (28) 12 (38) 30 (34)
Severe IVH (grade 3 or 4) 2 (10) – 2 (6) 3 (3)
Periventricular leucomalacia 1 (5) 5 (5) 3 (9) 3 (3)
Blood transfusion 10 (50) 46 (43) 10 (31) 45 (52)
Jaundice requiring treatment 18 (90) 98 (92) 31 (97) 80 (92)
Chronic lung disease 9 (45) 29 (27) 8 (25) 31 (36)
Ventilation 16 (80) 77 (72) 23 (72) 68 (78)
Necrotising enterocolitis 1 (5) 6 (6) 1 (3) 2 (2)
Sepsis* 13 (65) 55 (51) 17 (53) 54 (62)
Treatment for patent ductus arteriosis 5 (25) 15 (14) 1 (3) 16 (18)
Duration of hospital stay (nights)
  Median (25th, 75th centile) 64 (48, 105.5) 57 (38, 80) 46 (36, 63.5) 60 (40, 83)
Receiving mother’s breast milk at discharge† 10 (50) 61 (57) 13 (41) 54 (62)
*Clinical sepsis defined as positive culture and ≥5 days antibiotics or negative culture and ≥5 days antibiotics.
†Receiving breast milk at discharge not known for two babies in the clamp cord ≥2 min group with main outcome data available and one baby in both groups with no main 
outcome data available.
IVH, intraventricular haemorrhage.
Table 2 For children included in follow-up and eligible for 
neurodevelopmental assessment (at 2 years corrected age), 
information about the assessment
Clamp 
≥2 min+neonatal care 
with cord intact
Clamp ≤20 s
+neonatal care after 
clamping
n=124 (%) n=114 (%)
Any neurodevelopment data 107 (86) 87 (76)
Bayley-III and/or ASQ-3 87 (70) 68 (60)
  Bayley-III+ASQ-3 62 50
  Bayley-III only 4 3
  ASQ-3 only 21 15
Clinical data only 20 (16)* 19 (17)
Age (corrected) at Bayley-III 
(months)
  <24 2 7
  ≥24 to <27 53 37
  ≥27 to <30 9 9
  ≥30 2 -
ASQ-3 version (months)
  24 78 60
  27 3 3
  30 2 2
No neurodevelopmental data 17 (14) 27 (24)
*Information from parent only for one child.
ASQ-3, Ages and Stages Questionnaire-3.
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resulTs
Of the 238 children eligible for assessment, 27 were lost to 
follow-up, consent was withdrawn for a further 8 and for 9, 
there were insufficient data for analysis (figure 1). Therefore, 
194 children were assessed at 2 years corrected age. As there 
were 24 deaths, 218 children were included in the analysis of the 
main outcome (115 allocated deferred clamping (≥2 min); 103 
allocated immediate clamping (≤20 s)) (figure 1).
baseline characteristics and outcomes to discharge
Baseline characteristics and outcomes at discharge were similar 
for children included in the analysis of outcomes to discharge 
(n=270) and those included in the analysis of outcomes at 2 
years (n=218) (table 1). For children included in analysis of 
outcomes at 2 years, baseline characteristics remained balanced 
between the allocated groups, with a median gestation at birth 
of 29 weeks (table 1).
neurodevelopmental assessment
Data were available for 194/238 (82%) children alive at 2 years 
corrected age (table 2). Bayley-III data were available for 119/238 
(50%) children, with a higher percentage allocated deferred 
clamping (66/124, 53%) than immediate clamping (53/114, 
46%; table 2) being assessed. Corrected age at assessment was 
similar between groups. For 24 children with Bayley-III data, 
one or more scales were incomplete (13 deferred clamping, 11 
immediate clamping); for 18, this was the motor scale. Inter-
rater reliability of Bayley-III assessments was excellent with 97% 
agreement for the cognitive scale, 97% for language and 100% 
for motor (data not shown).
ASQ-3 data were available for 148/238 (62%) children, again 
with a higher response for those allocated deferred clamping 
(83/124, 67%) than immediate clamping (65/114, 57%) (table 2). 
For most children (138), the 24-month ASQ-3 was completed. 
The main reason for having neither Bayley-III nor ASQ-3 data 
was no response to the invitation to participate (72 children).
Routine clinical data were obtained for 39/238 (16%) children 
with neither ASQ-3 nor Bayley-III data (20 deferred clamping, 
19 immediate clamping; table 2).
For children allocated deferred clamping, there was some 
evidence that those lost to follow-up had poorer outcomes at 
discharge than those who were assessed (table 3). In this group, a 
greater percentage of children with no neurodevelopmental data 
had IVH, blood transfusion or chronic lung disease compared 
with those with data. This was not observed for children allo-
cated immediate clamping where there was some evidence of the 
opposite trend (table 3).
Death and adverse neurodevelopmental outcomes
Of children allocated deferred clamping, 24/115 (21%) died or 
had an adverse neurodevelopmental outcome compared with 
35/103 (34%) allocated immediate clamping (table 4); RR 0.61 
(95% CI 0.39 to 0.96); RD −13% (95% CI −25% to −1%). 
Using multiple imputation to account for loss to follow-up gave 
RR 0.69 (95% CI 0.44 to 1.09) and RD −9% (95% CI −21% 
to 2%).
In the deferred clamping group, 8/115 (7%) children died 
compared with 16/103 (16%) in the immediate clamping group 
(table 4). Of these, 3 were stillborn (1 deferred clamping, 2 
immediate clamping), 19 died before discharge from hospital 
(6 deferred clamping, 13 immediate clamping) and 2 died after 
discharge (one in each group). Of children alive at 2 years, 
16/107 (15%) allocated deferred clamping had an adverse 
neurodevelopmental outcome compared with 19/87 (22%) allo-
cated immediate clamping.
Of children with a neurodevelopmental assessment, the most 
common type of adverse outcomes were in speech/language 
and cognitive impairment (table 4). Summary statistics for the 
24-month ASQ-3 and Bayley-III are available in online supple-
mentary appendix 2.
DIsCussIOn
Follow-up of children in the Cord Pilot Trial at 2 years corrected 
age suggests that deferring cord clamping for at least 2 min 
and providing immediate neonatal care, if needed, with cord 
intact may reduce the risk of death or adverse neurodevelop-
mental outcome compared with immediate clamping (≤20 s) 
and neonatal care after clamping. However, these results were 
sensitive to imputation to account for missing data. More chil-
dren allocated deferred clamping had neurodevelopmental 
assessment data available; however, these children appeared to 
have fared slightly better at hospital discharge than those with 
missing follow-up data. In the immediate clamping group, there 
was evidence of the opposite trend when outcomes at discharge 
were compared according to availability of neurodevelopmental 
assessment data. Since the trial was not powered to demonstrate 
clinically important differences in outcome, confirmation is 
required in large high-quality randomised trials.
Strengths of our trial were that clamping was deferred for 
longer than in other trials at very preterm birth and that imme-
diate neonatal care (including stabilisation and resuscitation), if 
needed, was provided with the cord intact.20 Providing neonatal 
care with the cord intact allowed high-risk babies needing imme-
diate resuscitation at birth to be randomised, a group largely 
excluded from previous trials.21
Table 4 Death or adverse neurodevelopmental outcome at age 2 years (corrected)
Clamp ≥2 min+neonatal care 
with cord intact n=115 (%)
Clamp ≤20 s+neonatal care 
after clamping n=103 (%)
risk difference
(95% CI)
risk ratio
(95% CI)
Death or adverse neurodevelopmental outcome 24 (21) 35 (34) −13% (−25% to −1%) 0.61 (0.39 to 0.96)
  Death 8 (7) 16 (16) −9% (−17% to 0%) 0.45 (0.20 to 1.00)
  Adverse neurodevelopmental outcome 16 (14) 19 (18) −5% (−14% to 5%) 0.75 (0.41 to 1.39)
For children alive at 2 years, type of adverse neurodevelopment outcome*
  Motor 2 (2) 5 (6)
  Cognitive 11 (10) 6 (7)
  Hearing 2 (2) 2 (2)
  Speech/language 9 (8) 14 (16)
  Vision 2 (2) 2 (2)
*For: clamp ≥2 min+neonatal care with cord intact n=107; clamp ≤20 s+neonatal care after clamping n=87.
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A composite of death and adverse neurodevelopment was 
chosen as the main outcome, a decision supported by our parent 
representatives as being relevant to parents. Despite the prob-
lems of composite outcomes, this is considered acceptable for 
perinatal and neonatal trials provided it is likely that the direc-
tion of effect is the same for all components of the composite22 
as is the case for alternative policies for cord clamping. In our 
trial, the overall reduction in death or adverse neurodevelop-
ment in the deferred clamping group was primarily due to the 
reduction in death before discharge. There was no clear evidence 
of a difference between groups in adverse neurodevelopmental 
outcome or death after discharge.
Achieving high response rates for long-term follow-up is 
necessary to ensure sample representation; however, this is 
challenging. In order to achieve our 82% response rate, this 
necessitated employing multiple approaches and combining 
results obtained from different assessment tools, including diag-
nostic tests (Bayley-III), parent questionnaires (ASQ-3) and data 
obtained from routine clinical assessments. As screening tests 
may have poor diagnostic accuracy compared with gold standard 
tests23 and routine clinical assessments have poor sensitivity for 
evaluating cognitive outcomes in this population,24 this approach 
represents a limitation of our study. Future trials should attempt 
to attain long-term follow-up rates in excess of 90% and use a 
single standardised test to assess neurodevelopmental outcomes. 
Lower follow-up for children allocated immediate clamping may 
have been due to the women feeling they were not part of the 
trial as they received usual care or being disappointed they did 
not receive the ‘intervention’ of deferred clamping.25
Using routine data for developmental assessment in perinatal 
trials merits further evaluation as it is less intrusive for parents 
and less costly in terms of resources. In the UK, the National 
Institute for Health and Care Excellence has recently introduced 
guidance that high-risk children, such as those born before 
30 weeks’ gestation, are eligible for enhanced developmental 
surveillance. This includes a developmental assessment at 2 years 
corrected age.26 Provided they are of sufficient quality, these data 
could be used to determine neurodevelopmental outcomes for 
children in future trials.
The most recent systematic review, which includes the Cord 
Pilot Trial, concluded that delayed clamping reduces hospital 
mortality compared with immediate clamping, with no clear 
effect on serious neonatal morbidity.7 This review emphasises the 
importance of follow-up for children recruited to both existing 
and future trials. The latter should be large enough to provide 
adequate power to detect clinically important differences in 
outcomes and will also need to achieve high follow-up rates to 
enable reliable comparisons of neurodevelopmental outcomes. 
Since providing robust evidence is likely to require multiple trials, 
a systematic review and individual participant data meta-analysis 
of cord management at preterm birth is underway.27
COnClusIOns
Follow-up of children in the Cord Pilot Trial suggests deferred 
clamping with immediate neonatal care, if needed, beside the 
mother may reduce the risk of death or adverse neurodevel-
opmental outcome at 2 years corrected age compared with 
immediate clamping and neonatal care after clamping. Large 
high-quality trials are needed to confirm the true benefits and 
harms.
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